We provide investment recommendation to complement the last-minute
expert consensus on Medicenna Therapeutics Corp. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Medicenna TherapeuticsCorp income statement, its balance sheet, and the statement of cash flows. Potential Medicenna TherapeuticsCorp investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Medicenna TherapeuticsCorp investors may use each financial statement separately, they are all related. The changes in Medicenna TherapeuticsCorp's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Medicenna TherapeuticsCorp's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Medicenna TherapeuticsCorp
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Medicenna TherapeuticsCorp performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Medicenna TherapeuticsCorp shares is the value that is considered the true value of the share. If
the intrinsic value of Medicenna is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Medicenna TherapeuticsCorp. Please read more on our
fundamental analysis page.
Watch out for price decline
Please consider monitoring Medicenna TherapeuticsCorp on a daily basis if you are holding a position in it. Medicenna TherapeuticsCorp is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Medicenna TherapeuticsCorp stock to be traded above the $1 level to remain listed. If Medicenna TherapeuticsCorp stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Medicenna TherapeuticsCorp's Liquidity
Medicenna TherapeuticsCorp
financial leverage refers to using borrowed capital as a funding source to finance Medicenna TherapeuticsCorp ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Medicenna TherapeuticsCorp financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Medicenna TherapeuticsCorp's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Medicenna TherapeuticsCorp's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Medicenna TherapeuticsCorp's total debt and its cash.
Breaking it down a bit more
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Medicenna Therapeutics is not uncomon. Institutional investor usually refers to an organization that invests money in Medicenna Therapeutics on behalf of clients or other money managers. Buying and selling of large positions of Medicenna Therapeutics stock by institutional investors can create supply and demand imbalances that result in sudden price moves of Medicenna Therapeutics stock. Let's take a look at how the ownership of Medicenna is distributed among investors.
Ownership Allocation
Medicenna Therapeutics maintains a total of fifty-three million nine hundred eighty thousand
outstanding shares. Medicenna Therapeutics Corp holds significant amount of outstanding shares owned by
insiders. An
insider is usually defined as a CEO, other corporate executive, director, or
institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
| Retail Investors59.48% | Insiders33.16% | Institutions7.36% |
| Retail Investors | 59.48 |
| Insiders | 33.16 |
| Institutions | 7.36 |
| 2019 | 2020 | 2021 | 2022 (projected) |
Current Assets | 37.85 M | 42.15 M | 48.47 M | 41.94 M | Total Assets | 38 M | 42.25 M | 48.59 M | 42.06 M |
Asset Utilization
One of the ways to look at asset utilization of Medicenna is to check how much profit was generated for every dollar of assets it reports. Medicenna Therapeutics Corp secures a negative usage of assets of -50.17 %, losing $0.5 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Medicenna Therapeutics Corp shows how discouraging it operates for each dollar spent on its assets.
| Current Assets | 41.94 Million | 99.55 |
| Assets Non Current | 125,680 | 0.3 |
| Goodwill | 65,660.35 | 0.16 |
Our Medicenna analysis suggests possible reversion in July
The information ratio is down to -0.13 as of today. Medicenna Therapeutics Corp exhibits very low volatility with skewness of 0.79 and kurtosis of 2.51. However, we advise investors to further study Medicenna Therapeutics Corp technical indicators to make sure all market info is available and is reliable. Medicenna Therapeutics Corp is a potential penny stock. Although Medicenna Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Medicenna Therapeutics Corp. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Medicenna instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
Our Final Take On Medicenna Therapeutics
Whereas some firms in the biotechnology industry are either recovering or due for a correction, Medicenna may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 21st of June 2022, our final 90 days buy-sell recommendation on the company is
Cautious Hold. We believe Medicenna Therapeutics is
undervalued with
quite high probability of distress for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Medicenna TherapeuticsCorp. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com